Kyntra Bio Inc (KYNB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 06-2023 | 03-2023 | 12-2022 | 09-2022 | 06-2022 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 152,585 | 188,550 | 155,700 | 155,960 | 167,758 |
| Marketable Securities | 183,131 | 167,399 | 266,308 | 252,560 | 270,375 |
| Receivables | 25,599 | 17,654 | 16,299 | 15,328 | 33,573 |
| Inventories | 41,179 | 42,456 | 40,436 | 39,950 | 40,899 |
| TOTAL | $411,357 | $430,549 | $492,826 | $474,224 | $520,643 |
| Non-Current Assets | |||||
| PPE Net | 16,829 | 18,693 | 20,605 | 22,287 | 24,505 |
| Investments And Advances | 6,112 | 5,884 | 9,409 | 22,411 | 50,414 |
| Other Non-Current Assets | 80,829 | 83,418 | 87,247 | 89,915 | 91,227 |
| TOTAL | $103,770 | $107,995 | $117,261 | $134,613 | $166,146 |
| Total Assets | $515,127 | $538,544 | $610,087 | $608,837 | $686,789 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 12,802 | 71,282 | 30,758 | 19,323 | 29,360 |
| Accrued Expenses | 162,769 | 157,042 | 219,773 | 213,806 | 193,099 |
| TOTAL | $194,072 | $254,746 | $273,562 | $251,994 | $240,340 |
| Non-Current Liabilities | |||||
| Long Term Debt | 71,408 | N/A | N/A | N/A | N/A |
| Deferred Revenues | 7,490 | 16,495 | 12,739 | 7,361 | 6,897 |
| Other Non-Current Liabilities | 166,018 | 149,594 | 152,283 | 110,812 | 117,351 |
| TOTAL | $402,842 | $312,683 | $338,005 | $310,570 | $322,702 |
| Total Liabilities | $596,914 | $567,429 | $611,567 | $562,564 | $563,042 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 3,928 | 3,903 | 3,767 | 3,758 | 3,750 |
| Common Shares | 982 | 966 | 942 | 939 | 937 |
| Retained earnings | -1,722,073 | -1,634,393 | -1,557,688 | -1,491,513 | -1,399,863 |
| Other shareholders' equity | 14,237 | 15,397 | 14,247 | 12,621 | 13,037 |
| TOTAL | $-81,787 | $-28,885 | $-1,480 | $46,273 | $123,747 |
| Total Liabilities And Equity | $515,127 | $538,544 | $610,087 | $608,837 | $686,789 |